Price
$77.44+17.42%Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John D. Quisel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 165
- Beta
- 2.01
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 16.80
Financials
Net Income
$-59.53MEBITDA
$-57.62MFree Cash Flow
$-40.20MEPS (diluted)
$-1.53Shares Outstanding (diluted)
38.90M+2404.3%Operating Expenses
$64.16MCash & Debt
$682.82MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-212.18M | $-6.01 |
| 2024 | $0.00 | $-109.36M | $-3.96 |
| 2023 | $0.00 | $-76.43M | $-3.42 |
| 2022 | $0.00 | $-46.83M | $-45.05 |
| 2021 | $0.00 | $-35.97M | $-44.88 |
| 2020 | $0.00 | $-40.84M | $-27.02 |
Valuation
IRONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (16)
- Newszacks.com·2d ago·Neutral
Wall Street Analysts Think Disc Medicine, Inc. (IRON) Could Surge 64.74%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 64.7% in Disc Medicine, Inc. (IRON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newsseekingalpha.com·5d ago·Neutral
Disc Medicine, Inc. (IRON) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript Disc Medicine, Inc. (IRON) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Disc Medicine to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that company management will participate in fireside chats at upcoming investor conferences:
View source ↗ - Newsglobenewswire.com·33d ago·Negative
…c Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an upsized underwritten public offering of shares of its common stock. Disc is selling 6,000,000 shares of …
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
…ounces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the commencement of an underwritten public offering of $350 million of shares of its common stock and, in lieu of common s…
View source ↗ - Newsseekingalpha.com·34d ago·Positive
Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript
View source ↗ - Newsbenzinga.com·34d ago·Neutral
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study Disc Medicine Inc. (NASDAQ:IRON) on Monday reported positive topline results from its APOLLO Phase 3 trial evaluating bitopertin for erythropoietic protoporphyria, or EPP, including X-linked protoporphyria, or XLP.
View source ↗ - Newsinvezz.com·34d ago·Neutral
Disc Medicine stock soars: take profit or buy into strength? Disc Medicine (IRON) shares ripped higher on Monday morning after the company's experimental blood-disorder treatment, bitopertin, delivered positive Phase 3 results. In its press release, management said the APOLLO clinical trial met every primary and secondary endpoint, strengthening the firm's case for another FDA submission.
View source ↗ - Newsmarketbeat.com·34d ago·Negative
Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission Disc Medicine NASDAQ: IRON said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), supporting the company's plan to resubmit a new drug application to the U.S. Food and Drug Administration by the end of the year.
View source ↗ - Newsbarrons.com·34d ago·Negative
Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.
View source ↗ - Newsproactiveinvestors.com·34d ago·Negative
Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints Disc Medicine (NASDAQ:IRON), the clinical-stage biopharmaceutical company, surged 38% to $78.24 on Monday after its experimental drug bitopertin met every endpoint in a pivotal phase 3 trial. The APOLLO trial results strengthened the prospects for bitopertin as a treatment for erythropoietic protoporphyria (EPP), a rare disease that causes severe pain and skin reactions when patients are exposed to sunlight.
View source ↗ - Newsreuters.com·34d ago·Negative
Disc Medicine's rare disease drug succeeds in late-stage trial Disc Medicine's rare disease drug succeeds in late-stage trial
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Disc Medicine, Inc. (IRON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Disc Medicine, Inc. (IRON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·76d ago·Negative
IRON, the World's First Advanced General-Purpose Humanoid Robot, Walks off the Production Lines as XPENG's Humanoid Robot Manufacturing Facility Is Officially Commissioned XPENG has officially commissioned its humanoid robot production lines and completed the production-lines manufacturing of the world's first advanced humanoid robot, which autonomously walked off the lines, marking a critical leap from R&D prototyping to production-lines manufacturing. XPENG's humanoid robot production lines fe…
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
Disc Medicine to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:
View source ↗ - Newsaccessnewswire.com·102d ago·Negative
Bolt Metals to Rebrand as 26 Metals Inc. and Adopt the Ticker "IRON," Highlighting Its Focus on Flagship Florália Iron Project in Brazil's Iron Quadrangle New name and symbol mark the Company's transformation into a focused, near-term iron developer — anchored by a high-grade, low-carbon, infrastructure-rich project in the heart of one of the world's premier iron ore districts. VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:BOLT)(OTCQB:PCRCF)
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-1.47 per share
Typical surprise -3.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-1.53 vs $-1.63beat
- Thu, Jul 30$-1.54 vs $-1.71beat
- Tue, May 5$-1.65 vs $-1.55miss
- Thu, Feb 26$-1.62 vs $-1.69beat
- Thu, Nov 6$-1.77 vs $-1.48miss
- Thu, Aug 7$-1.58 vs $-1.17miss
Estimates and results for IRON via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IRON officers and directors.
- Bought
- —
- Sold
- $23.6m
0 trades
53 trades
- Savage William Jacobsold
- Bitterman Kevinsold
- Bitterman Kevinsold
- Bitterman Kevinsold
- Bitterman Kevinsold
- Bitterman Kevinsold
- Bitterman Kevinsold
- Bitterman Kevinsold
47 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IRON.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
